Last reviewed · How we verify
Multiple Myeloma
Approved treatments
- Pf-07284890 · Pfizer
- Pf-04171327 · Pfizer
PF-04171327 is a nonsteroidal but steroid-like selective glucocorticoid receptor modulator (SGRM). - Aphexda · Ayrmid Pharma
Aphexda works by binding to its target, which is currently unknown, to exert its therapeutic effects. - Wydase · Baxter
Hyaluronidase increases tissue permeability by breaking down hyaluronic acid, promoting the diffusion and absorption of injected fluids. - Farydak · Secura
- Decadron-La · Merck & Co.
- Gliadel · Avet Lifesciences
Gliadel works by attaching an alkyl group to the DNA of cancer cells, interfering with their ability to replicate and grow. - Ninlaro · Millennium Pharms
Ninlaro works by blocking the proteasome, a cellular complex that breaks down proteins, leading to cell death in cancer cells. - Mozobil · Sanofi
Mozobil works by binding to the C-C chemokine receptor type 2, which helps to mobilize hematopoietic stem cells from the bone marrow into the bloodstream. - Hu38Sb19 · Sanofi
Isatuximab works by binding to the CD38 protein on cancer cells, triggering a response that leads to their destruction. - Pf-07985631 · Pfizer
- Decadron · Generic (originally Merck)
- Farydak · Novartis Pharmaceuticals
- Pf-07220060 · Pfizer
- Pf-07248144 · Pfizer
- alkeran · French Innovative Leukemia Organisation
- Pf-07264660 · Pfizer
The mechanism of action of PF-07264660 is not specified. - Pf-07293893 · Pfizer
- adriacin · Chipscreen Biosciences, Ltd.
- Kyprolis · Black Sea Hematology Association
- Hydroxydaunorubicin · University of Colorado, Denver
- Thalomid · Ann & Robert H Lurie Children's Hospital of Chicago
- Cyclophosphamid · Zhejiang University
- Blenrep · Duke University
- Revlimid · Bristol-Myers Squibb
Lenalidomide targets cereblon to degrade substrate proteins, inducing cytotoxicity and immunomodulation. - Velcade · University of Arkansas
- Pf-08032562 · Pfizer Inc.
- Pf-07940369 · Pfizer Inc.
- SARCLISA · SANOFI AVENTIS US
- Pf-07284892 · Pfizer
- Oral PF-07220060 · Pfizer
- Thalomid · Bristol-Myers Squibb
Thalomid works by inhibiting the production of tumor necrosis factor, a protein that promotes inflammation and tumor growth. - Velcade · Shilpa
Reversible inhibitor of 26S proteasome chymotrypsin-like activity preventing ubiquitinated protein degradation. - Blenrep · GSK
Belantamab mafodotin binds to BCMA on multiple myeloma cells, is internalized, and releases a cytotoxic agent that disrupts microtubules, causing cell death. - Pf-07923568 · Pfizer
- Carmustin · University Hospital Freiburg
- Mozobil · University of Washington
- Kyprolis · Amgen
Kyprolis works by blocking the proteasome, a complex that breaks down proteins in cells. - Pf-08049820 Mr2 · Pfizer
- Cytoxan (Lyophilized) · Baxter
Cyclophosphamide cross-links tumor cell DNA and interferes with malignant cell growth through active alkylating metabolites. - Ninlaro · Takeda
Ninlaro blocks the action of proteasomes, which are cellular complexes that break down and recycle proteins. - Huluc63 · Bristol-Myers Squibb
Huluc63 works by binding to the SLAMF7 protein on the surface of cancer cells, stimulating the immune system to attack and kill the cells. - Liposomal Doxorubicin · Pfizer
- PF-06863135 + dexamethasone · Pfizer
- Darzalex · Johnson & Johnson
Daratumumab binds CD38 on tumor cells, inducing apoptosis and immune-mediated lysis via CDC, ADCC, and ADCP. - POMA · Bristol
Poma is a small molecule that works by interacting with a specific biological target to produce a therapeutic effect. - Alkeran · Apotex
- Doxorubicin Hydrochloride · Pfizer
Doxorubicin works by intercalating DNA strands and inhibiting topoisomerase II, an enzyme essential for DNA replication and cell division. - Cytoxan (Lyophilized) · Baxter
Cytoxan works by interfering with the DNA replication process in rapidly dividing cancer cells. - Pomalyst · Bristol-Myers Squibb
Pomalyst works by binding to the cereblon protein, which disrupts the function of certain genes involved in cancer cell growth.
Clinical guidelines
- FDA label — 1L
DARZALEX FASPRO in combination with bortezomib, lenalidomide, and dexamethasone for induction and consolidation in newly diagnosed patients who are eligible for autologous stem cell transplant. - FDA label — 1L
DARZALEX FASPRO in combination with bortezomib, lenalidomide, and dexamethasone in newly diagnosed patients who are ineligible for autologous stem cell transplant. - FDA label — 1L
DARZALEX FASPRO in combination with bortezomib, melphalan, and prednisone in newly diagnosed patients who are ineligible for autologous stem cell transplant. - FDA label — 1L
DARZALEX FASPRO in combination with lenalidomide and dexamethasone in newly diagnosed patients who are ineligible for autologous stem cell transplant. - FDA label — 2L
DARZALEX FASPRO in combination with lenalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma who have received at least one prior therapy. - FDA label — 2L
DARZALEX FASPRO in combination with bortezomib, thalidomide, and dexamethasone in newly diagnosed patients who are eligible for autologous stem cell transplant. - FDA label — 2L
DARZALEX FASPRO in combination with bortezomib and dexamethasone in patients who have received at least one prior therapy. - FDA label — 2L
DARZALEX FASPRO in combination with pomalidomide and dexamethasone in patients who have received at least one prior line of therapy including lenalidomide and a proteasome inhibitor. - FDA label — 2L
DARZALEX FASPRO in combination with carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma who have received one to three prior lines of therapy. - FDA label — 3L+
DARZALEX FASPRO as monotherapy in patients who have received at least three prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory agent or who are double-refractory to a PI and an immunomodulatory agent. - FDA label — any
Bortezomib for injection is indicated for the treatment of adult patients with multiple myeloma. - FDA label — any
Bortezomib for injection is indicated for the treatment of adult patients with mantle cell lymphoma. - FDA label — any
Bortezomib for injection is indicated for the treatment of adult patients with systemic AL amyloidosis. - FDA label — 2L|3L
EMPLICITI in combination with lenalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received one to three prior therapies. - FDA label — 3L+
Pomalidomide, in combination with dexamethasone, is indicated for adult patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or within 60 days of completion of the last therapy. - FDA label — 2L|3L
Kyprolis is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy in combination with Lenalidomide and dexamethasone; or Dexamethasone; or Daratumumab and dexamethasone; or Daratumumab and hyaluronidase-fihj and dexamethasone; or Isatuximab and dexamethasone. - FDA label — 2L+
Kyprolis is indicated as a single agent for the treatment of adult patients with relapsed or refractory multiple myeloma who have received one or more lines of therapy. - FDA label — 1L|2L|3L+
Lenalidomide in combination with dexamethasone is indicated for the treatment of adult patients with multiple myeloma. - FDA label — 2L
DOXIL liposomal infusion, in combination with bortezomib, is indicated for the treatment of patients with multiple myeloma who have not previously received bortezomib and have received at least one prior therapy.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape: